1. Home
  2. VVOS vs PHIO Comparison

VVOS vs PHIO Comparison

Compare VVOS & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

15.1M

Sector

Health Care

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.28

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVOS
PHIO
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.1M
14.6M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
VVOS
PHIO
Price
$1.31
$1.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$6.25
$10.67
AVG Volume (30 Days)
109.4K
306.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
80.07
N/A
EPS
N/A
N/A
Revenue
$15,031,000.00
N/A
Revenue This Year
$31.42
N/A
Revenue Next Year
$49.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.91
N/A
52 Week Low
$1.09
$0.81
52 Week High
$7.40
$4.19

Technical Indicators

Market Signals
Indicator
VVOS
PHIO
Relative Strength Index (RSI) 50.58 55.82
Support Level N/A $1.11
Resistance Level $1.50 $1.43
Average True Range (ATR) 0.12 0.08
MACD 0.02 0.00
Stochastic Oscillator 64.38 68.18

Price Performance

Historical Comparison
VVOS
PHIO

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: